Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.35 |
| ▸ | GLS | O94925 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15657238 | 0.86 | NR1H2 (0.41) | NR1H2NAMPTGPR119USP2SMN1; SMN2 | |
| SCHEMBL16862541 | 0.86 | NR1H2 (0.39) | NR1H2NAMPTGPR119USP2SMN1; SMN2 | |
| SCHEMBL2355900 | 0.85 | NR1H2 (0.57) | NR1H2NAMPTGLSUSP2SMN1; SMN2 | |
| SCHEMBL445759 | 0.84 | NR1H2 (0.51) | NR1H2NAMPTGPR119USP2SMN1; SMN2 | |
| SCHEMBL18210171 | 0.82 | NR1H2 (0.46) | NR1H2NAMPTGLSUSP2SMN1; SMN2 | |
| SCHEMBL371676 | 0.79 | NR1H2 (0.65) | NR1H2NAMPTGPR119USP2SMN1; SMN2 | |
| SCHEMBL903879 | 0.79 | NR1H2 (0.65) | NR1H2NAMPTGPR119USP2SMN1; SMN2 | |
| SCHEMBL1225473 | 0.79 | NR1H2 (0.65) | NR1H2NAMPTGPR119USP2SMN1; SMN2 | |
| SCHEMBL30164990 | 0.79 | NR1H2 (0.57) | NR1H2NAMPTGPR119USP2SMN1; SMN2 | |
| SCHEMBL343551 | 0.77 | NR1H2 (0.55) | NR1H2NAMPTGPR119SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011103127-A1 | TREATMENT OF METABOLIC SYNDROME WITH PIPERIDINE AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2011-08-25 | — | — | WO | disclosed |